Aripiprazole in children with attention-deficit/hyperactivity disorder

Robert L Findling, Elizabeth J. Short, Thomas Leskovec, Lisa Townsend, Christine A. Demeter, Nora K. McNamara, Robert J. Stansbrey

Research output: Contribution to journalArticle

Abstract

Objective: To examine the effectiveness and cognitive effects of aripiprazole (APZ) in children with a primary diagnosis of attention-deficit/ hyperactivity disorder (ADHD). Methods: Youths, ages 8-12 years, with a diagnosis of ADHD combined-type or ADHD predominately inattentive-type were enrolled into a 6-week, open-label pilot trial. Outcome measures included the ADHD Rating Scale-IV (ARS-IV), Clinical Global Impressions Scale (CGI), and Children's Global Assessment Scale (CGAS). The Conners' Continuous Performance Test II, Reading and Math Fluency subscales of the Woodcock-Johnson III Tests of Achievement, and the Stroop Color and Word Test were administered at baseline and end of study. Results: Fourteen (9 males and 5 females) youths were diagnosed with ADHD-combined type, while 9 (5 males and 4 females) were diagnosed with ADHD-inattentive type. At a mean dose of 6.7 mg/day, end of study results showed overall significant improvement from baseline on ADHD and functional outcome measures. No significant differences in baseline performance at end of study were found on the cognitive measures. The most frequently reported adverse events were sedation (n = 18; 78.3%) and headache (n = 11; 47.8%). Conclusions: Although this was a brief pilot study with a small sample size, in this cohort, APZ led to clinical benefit in reducing ADHD symptoms and improving overall functioning. Of note, cognitive functioning did not appear to be negatively impacted by APZ treatment.

Original languageEnglish (US)
Pages (from-to)347-354
Number of pages8
JournalJournal of Child and Adolescent Psychopharmacology
Volume18
Issue number4
DOIs
StatePublished - Aug 1 2008
Externally publishedYes

Fingerprint

Attention Deficit Disorder with Hyperactivity
Outcome Assessment (Health Care)
Stroop Test
Aripiprazole
Sample Size
Headache
Reading
Color

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Findling, R. L., Short, E. J., Leskovec, T., Townsend, L., Demeter, C. A., McNamara, N. K., & Stansbrey, R. J. (2008). Aripiprazole in children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 18(4), 347-354. https://doi.org/10.1089/cap.2007.0124

Aripiprazole in children with attention-deficit/hyperactivity disorder. / Findling, Robert L; Short, Elizabeth J.; Leskovec, Thomas; Townsend, Lisa; Demeter, Christine A.; McNamara, Nora K.; Stansbrey, Robert J.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 18, No. 4, 01.08.2008, p. 347-354.

Research output: Contribution to journalArticle

Findling, RL, Short, EJ, Leskovec, T, Townsend, L, Demeter, CA, McNamara, NK & Stansbrey, RJ 2008, 'Aripiprazole in children with attention-deficit/hyperactivity disorder', Journal of Child and Adolescent Psychopharmacology, vol. 18, no. 4, pp. 347-354. https://doi.org/10.1089/cap.2007.0124
Findling, Robert L ; Short, Elizabeth J. ; Leskovec, Thomas ; Townsend, Lisa ; Demeter, Christine A. ; McNamara, Nora K. ; Stansbrey, Robert J. / Aripiprazole in children with attention-deficit/hyperactivity disorder. In: Journal of Child and Adolescent Psychopharmacology. 2008 ; Vol. 18, No. 4. pp. 347-354.
@article{f8d83d4a544549d8a85e89c7c755dcdb,
title = "Aripiprazole in children with attention-deficit/hyperactivity disorder",
abstract = "Objective: To examine the effectiveness and cognitive effects of aripiprazole (APZ) in children with a primary diagnosis of attention-deficit/ hyperactivity disorder (ADHD). Methods: Youths, ages 8-12 years, with a diagnosis of ADHD combined-type or ADHD predominately inattentive-type were enrolled into a 6-week, open-label pilot trial. Outcome measures included the ADHD Rating Scale-IV (ARS-IV), Clinical Global Impressions Scale (CGI), and Children's Global Assessment Scale (CGAS). The Conners' Continuous Performance Test II, Reading and Math Fluency subscales of the Woodcock-Johnson III Tests of Achievement, and the Stroop Color and Word Test were administered at baseline and end of study. Results: Fourteen (9 males and 5 females) youths were diagnosed with ADHD-combined type, while 9 (5 males and 4 females) were diagnosed with ADHD-inattentive type. At a mean dose of 6.7 mg/day, end of study results showed overall significant improvement from baseline on ADHD and functional outcome measures. No significant differences in baseline performance at end of study were found on the cognitive measures. The most frequently reported adverse events were sedation (n = 18; 78.3{\%}) and headache (n = 11; 47.8{\%}). Conclusions: Although this was a brief pilot study with a small sample size, in this cohort, APZ led to clinical benefit in reducing ADHD symptoms and improving overall functioning. Of note, cognitive functioning did not appear to be negatively impacted by APZ treatment.",
author = "Findling, {Robert L} and Short, {Elizabeth J.} and Thomas Leskovec and Lisa Townsend and Demeter, {Christine A.} and McNamara, {Nora K.} and Stansbrey, {Robert J.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1089/cap.2007.0124",
language = "English (US)",
volume = "18",
pages = "347--354",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Aripiprazole in children with attention-deficit/hyperactivity disorder

AU - Findling, Robert L

AU - Short, Elizabeth J.

AU - Leskovec, Thomas

AU - Townsend, Lisa

AU - Demeter, Christine A.

AU - McNamara, Nora K.

AU - Stansbrey, Robert J.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Objective: To examine the effectiveness and cognitive effects of aripiprazole (APZ) in children with a primary diagnosis of attention-deficit/ hyperactivity disorder (ADHD). Methods: Youths, ages 8-12 years, with a diagnosis of ADHD combined-type or ADHD predominately inattentive-type were enrolled into a 6-week, open-label pilot trial. Outcome measures included the ADHD Rating Scale-IV (ARS-IV), Clinical Global Impressions Scale (CGI), and Children's Global Assessment Scale (CGAS). The Conners' Continuous Performance Test II, Reading and Math Fluency subscales of the Woodcock-Johnson III Tests of Achievement, and the Stroop Color and Word Test were administered at baseline and end of study. Results: Fourteen (9 males and 5 females) youths were diagnosed with ADHD-combined type, while 9 (5 males and 4 females) were diagnosed with ADHD-inattentive type. At a mean dose of 6.7 mg/day, end of study results showed overall significant improvement from baseline on ADHD and functional outcome measures. No significant differences in baseline performance at end of study were found on the cognitive measures. The most frequently reported adverse events were sedation (n = 18; 78.3%) and headache (n = 11; 47.8%). Conclusions: Although this was a brief pilot study with a small sample size, in this cohort, APZ led to clinical benefit in reducing ADHD symptoms and improving overall functioning. Of note, cognitive functioning did not appear to be negatively impacted by APZ treatment.

AB - Objective: To examine the effectiveness and cognitive effects of aripiprazole (APZ) in children with a primary diagnosis of attention-deficit/ hyperactivity disorder (ADHD). Methods: Youths, ages 8-12 years, with a diagnosis of ADHD combined-type or ADHD predominately inattentive-type were enrolled into a 6-week, open-label pilot trial. Outcome measures included the ADHD Rating Scale-IV (ARS-IV), Clinical Global Impressions Scale (CGI), and Children's Global Assessment Scale (CGAS). The Conners' Continuous Performance Test II, Reading and Math Fluency subscales of the Woodcock-Johnson III Tests of Achievement, and the Stroop Color and Word Test were administered at baseline and end of study. Results: Fourteen (9 males and 5 females) youths were diagnosed with ADHD-combined type, while 9 (5 males and 4 females) were diagnosed with ADHD-inattentive type. At a mean dose of 6.7 mg/day, end of study results showed overall significant improvement from baseline on ADHD and functional outcome measures. No significant differences in baseline performance at end of study were found on the cognitive measures. The most frequently reported adverse events were sedation (n = 18; 78.3%) and headache (n = 11; 47.8%). Conclusions: Although this was a brief pilot study with a small sample size, in this cohort, APZ led to clinical benefit in reducing ADHD symptoms and improving overall functioning. Of note, cognitive functioning did not appear to be negatively impacted by APZ treatment.

UR - http://www.scopus.com/inward/record.url?scp=50849103679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50849103679&partnerID=8YFLogxK

U2 - 10.1089/cap.2007.0124

DO - 10.1089/cap.2007.0124

M3 - Article

C2 - 18759644

AN - SCOPUS:50849103679

VL - 18

SP - 347

EP - 354

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 4

ER -